Artificial Intelligence Governance in Health Systems: Systematic Review of Frameworks and Integrative Model Proposal - Takeaways - MDSpire

Artificial Intelligence Governance in Health Systems: Systematic Review of Frameworks and Integrative Model Proposal

  • By

  • Hassane Alami

  • Renata Pozelli Sabio

  • Elsury Johanna Pérez

  • Marie-Pierre Gagnon

  • Lyse Langlois

  • Jean-Louis Denis

  • Kathy Malas

  • Lysanne Rivard

  • Mathilde Savoldelli

  • Mohamed Ali Ag Ahmed

  • Jean-Paul Fortin

  • June 8, 2026

  • 0 min

Share

  • 1

    AI integration in healthcare systems presents both opportunities for efficiency and significant challenges, including ethical and clinical risks.

  • 2

    Existing ethical AI frameworks lack operational guidance, necessitating robust governance frameworks to translate principles into practice.

  • 3

    AI governance in healthcare must address interdependent dimensions, including sociopolitical, ethical, clinical, and data management issues.

  • 4

    A systematic review aims to synthesize current AI governance frameworks in healthcare and propose an integrative model for effective policy and practice.

  • 5

    Comprehensive AI governance frameworks are essential for ensuring safe, effective, and equitable integration of AI technologies in healthcare.

Original Source(s)

Artificial Intelligence Governance in Health Systems: Systematic Review of Frameworks and Integrative Model Proposal

  • by Hassane Alami, Renata Pozelli Sabio, Elsury Johanna Pérez, Marie-Pierre Gagnon, Lyse Langlois, Jean-Louis Denis, Kathy Malas, Lysanne Rivard, Mathilde Savoldelli, Mohamed Ali Ag Ahmed, Jean-Paul Fortin

  • June 8, 2026

Related Content

Electroacupuncture at LI11 and SP10 is associated with alleviation of acute urticaria-like reactions in passive cutaneous anaphylaxis: an exploratory analysis of complement-related proteins and multiscale omics

Chemoimmunotherapy Linked to HNSCC Response

Higher pathologic response rates with chemoimmunotherapy versus immunotherapy alone call for phase 3 trials, but survival implications remain unknown.

Oral HRS-7535 Lowered A1c in Trial

Nonpeptide oral agent requires no fasting administration.